CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
IPI-504drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00113204
NCT00113204Phase 1Completed
CompareCT.gov

A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma

Infinity Pharmaceuticals, Inc.·interventional·Posted Jun 7, 2005·Updated May 20, 2008

In Brief

A Phase 1 clinical trial evaluating IPI-504 for Multiple Myeloma. Completed, enrolled 18 participants across 4 sites.

Detailed Summary

This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 7, 2005
Enrollment StartJun 1, 2005
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 21.1 years ago

Interventions

IPI-504drug